UPenn Cancer Center offers prosate cancer prevention trial using selenium & vitamin E

January 24, 2002

(PHILADELHIA, PA) - Prostate cancer is the second-deadliest form of cancer, after lung cancer, for American men. According to the American Cancer Society, about 189,000 men in the US will be diagnosed with prostate cancer and more than 31,200 are expected to die of the disease in just this year alone. To help combat such alarming numbers, researchers at the University of Pennsylvania Cancer Center are looking for healthy men age 55 and older to participate in a study to determine if the two dietary supplements- selenium and vitamin E- can prevent prostate cancer.

Selenium, a natural mineral found in multivitamins and in many foods such as grains, corn, fish and animal organ meats, was originally investigated as a potential method of preventing skin cancer. "Previous research with vitamin E and selenium, in studies focusing on other types of cancer, suggested that together these nutrients might also prevent prostate cancer," says S. Bruce Malkowicz, MD, associate professor of Urology and principal investigator of the study. "What makes this study so appealing is that taking vitamin E and selenium, a natural vitamin and mineral found in many common foods, is completely non-toxic when taken in regulated dosages."

Penn, the coordinating site for 15 other Pennsylvania locations, is one of more than 400 sites in the United States, Puerto Rico, and Canada recruiting participants for this trial which is the largest-ever for prostate cancer prevention. The Selenium and Vitamin E Cancer Prevention Trial, or SELECT, is sponsored by the National Cancer Institute and the Southwest Oncology Group. It will include a total of 32,400 men and may take up to 12 years to complete.

Men of all races and ethnic background are encouraged to participate in the trial. African-American men have the highest incidence of prostate cancer in the world and are especially encouraged to consider joining the trial. The disease also strikes black men at a younger age, so they are eligible to enroll in the study at age 50, vs. age 55 for other racial and ethnic groups. There is no upper age limit for participation in the trial.

Selenium and vitamin E are antioxidants, capable of neutralizing toxins known as "free radicals," that might otherwise damage the genetic material of cells and possibly lead to cancer. These two naturally occurring nutrients were chosen for study because of the inadvertent results of two other large cancer prevention trials, one for non-melanoma skin cancer and the other for lung, in which prostate cancer rates were significantly reduced.

"This trial is the critical next step for pursuing the promising leads we've seen for prostate cancer prevention," said Malkowicz. "The only way to determine the real value of these supplements for prostate cancer is to do a large clinical trial focused specifically on this disease."

Study participants will be followed for five years and only have to visit the study site once every six months. Men may be able to participate in the SELECT trial if they:

Are age 55 or older; age 50 or older for black men;
Have never had prostate cancer and have not had any other cancer, except non-melanoma skin cancer, in the last five years;
Are generally in good health.
-end-
For more information about the selenium and vitamin E prostate cancer prevention trial at the University of Pennsylvania Cancer Center, please call 1-800-789-PENN and ask for the SELECT study.

University of Pennsylvania School of Medicine

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.